August 1, 2018 – Charleston, SC, USA – RichSource Stem Cells, Inc. (RichSource), a leader in the business development and distribution of human tissue allograft combination products and membranes, announced today its own brand product line: RICHGEN. With the introduction of this breakthrough line, the industry is no longer limited to single material post-birth, multipotent cellular products. Available throughout the U.S., the RICHGEN product line is backed by an experienced nationwide team of RichSource Area Vice Presidents who can educate, train and provide support to physician practices and networks. Additionally, RichSource’s simplified and more effective treatment protocols helps to optimize practices and patient results. [Read more…]
Fresenius Medical Care achieves preclinical milestone in its regenerative medicine program for chronic kidney disease
July 30, 2018 – Fresenius Medical Care, the world’s largest provider of dialysis products and services, announced today that its subsidiary Unicyte AG has achieved a key preclinical milestone in its regenerative medicine program for chronic kidney disease. The company was able to confirm a disease modifying potential for its proprietary nano-Extracellular Vesicles (“nEVs” are stem cell-derived particles that support communication between cells) in a second preclinical model of chronic kidney disease. [Read more…]
Irvine Scientific Introduces Chemically-Defined Natural Killer Cell Expansion Medium for Immunotherapy & Translational Research Applications
The first chemically-defined, animal component-free cell culture medium for natural killer (NK) cells
July 2018, Santa Ana, Calif. — Irvine Scientific, an industry leader in the development and manufacture of cell culture media, announced the introduction of PRIME-XV® NK Cell CDM— the first commercially available chemically-defined (CDM), animal component-free (ACF) medium for the ex vivo expansion of NK cells. The advanced medium delivers natural killer (NK) cell expansion while preserving NK cell potency and functionality. [Read more…]
Sangamo Therapeutics to Acquire Regulatory T Cell Leader TxCell for €72 Million
Sangamo Therapeutics (Nasdaq: SGMO) has announced it is acquiring TxCell S.A. (ENXTPA: TXCL) in a deal worth approximately €72 million. The deal is expected to be completed by the fourth quarter of 2018.
This acquisition will combine Sangamo’s unique ex vivo (outside the body) gene editing technology with TxCell’s CAR-Treg prowess, making Sangamo a new global leader in the Treg sector. [Read more…]
Exosomics Siena Launches Exosome-Based Liquid Biopsy Solutions for Selective Analysis of Tumor-Derived DNA and RNA
-
Lonza Pharma & Biotech backs Exosomics Siena S.p.A. as they launch first products for next-generation research and diagnostic applications.
-
Exosomics Siena’s technology to bring new, highly selective solutions for cancer detection, characterization and monitoring.
Siena (IT) and Basel (CH), 13 July 2018 – Exosomics Siena S.p.A., a pioneer and world leader in exosome-based diagnostics, today announced the launch of its first proprietary liquid biopsy solutions, SeleCTEV™ DNA and SortEV™ RNA, for the selective isolation of tumor-derived nucleic acids from complex biofluids such as plasma or serum. [Read more…]
- « Previous Page
- 1
- …
- 230
- 231
- 232
- 233
- 234
- …
- 338
- Next Page »